Related Experiment Video

Updated: Aug 23, 2026

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Hyperkalemic blood versus crystalloid cardioplegia in longer clamping times

Alexander A Albert1, Bert Arnrich, Jörg A Walter

  • 1Clinic for Cardiothoracic Surgery, Heart Institute Lahr/Baden, Germany. alexander.albert@heart-lahr.com

Asian Cardiovascular & Thoracic Annals
|June 24, 2004
PubMed

Insights

Cold hyperkalemic blood cardioplegia offers superior myocardial protection compared to crystalloid cardioplegia during coronary artery bypass grafting, especially with longer aortic crossclamp times.

Area of Science:

  • Cardiovascular Surgery
  • Cardioplegia Solutions
  • Myocardial Protection

Background:

  • Coronary artery bypass grafting (CABG) requires myocardial protection during aortic crossclamping.
  • The choice of cardioplegia solution impacts myocardial preservation and patient outcomes.
  • Crystalloid and blood cardioplegia are common methods for myocardial protection.

Purpose of the Study:

  • To compare the effectiveness of crystalloid versus cold hyperkalemic blood cardioplegia for myocardial protection in isolated CABG.
  • To investigate the relationship between aortic crossclamp time and myocardial injury (creatine kinase-MB release) with different cardioplegia strategies.

Main Methods:

  • Retrospective analysis of 715 patients receiving crystalloid cardioplegia and 5419 patients receiving cold hyperkalemic blood cardioplegia for isolated CABG (1996-2001).
  • Measurement of creatine kinase-MB levels preoperatively, 90 minutes, and 7 hours post-extracorporeal circulation.
  • Multivariate linear regression analysis to correlate post-bypass creatine kinase-MB release with aortic crossclamp time and cardioplegia type.

Main Results:

  • Higher creatine kinase-MB levels were observed 90 minutes post-bypass in the crystalloid cardioplegia group compared to the blood cardioplegia group.
  • A linear relationship existed between aortic crossclamp time and post-bypass creatine kinase-MB release in both groups.
  • Post-bypass creatine kinase-MB release increased significantly with longer aortic crossclamp times, and this increase was more pronounced with crystalloid cardioplegia (slope 0.230 vs. 0.106).
  • Intraaortic balloon pumping was used less frequently in the blood cardioplegia group.

Conclusions:

  • Cold hyperkalemic blood cardioplegia provides superior myocardial protection compared to crystalloid cardioplegia during isolated CABG.
  • Blood cardioplegia demonstrates an advantage in myocardial protection during extended aortic crossclamp times.
  • The findings support the use of blood cardioplegia for improved outcomes in patients undergoing CABG with potentially longer crossclamp durations.

More Related Videos

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest08:30

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest

Published on: August 6, 2015

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...